This article is within the scope of WikiProject Business, a collaborative effort to improve the coverage of
business articles on Wikipedia. If you would like to participate, please visit the project page, where you can join
the discussion and see a list of open tasks.BusinessWikipedia:WikiProject BusinessTemplate:WikiProject BusinessWikiProject Business articles
This article is within the scope of WikiProject Companies, a collaborative effort to improve the coverage of
companies on Wikipedia. If you would like to participate, please visit the project page, where you can join
the discussion and see a list of open tasks.CompaniesWikipedia:WikiProject CompaniesTemplate:WikiProject Companiescompany articles
This article is within the scope of WikiProject Japan, a collaborative effort to improve the coverage of Japan-related articles on Wikipedia. If you would like to
participate, please visit the
project page, where you can join the project, participate in
relevant discussions, and see
lists of open tasks. Current time in Japan: 14:02, June 17, 2024 (
JST,
Reiwa 6) (Refresh)JapanWikipedia:WikiProject JapanTemplate:WikiProject JapanJapan-related articles
This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of
Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join
the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
The
Wikimedia Foundation's
Terms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see
WP:PAID. For advice about reviewing paid contributions, see
WP:COIRESPONSE.
MaryGaulke (
talk·contribs) has been paid by Porter Novelli on behalf of Daiichi Sankyo.
Removed the erranous food/beverage analogy.
It doesn't belong in an encyclopedia entry for this company
Brettgo1 12:51, 22 October 2006 (UTC)reply
WikiProject class rating
This article was automatically assessed because at least one WikiProject had rated the article as stub, and the rating on other projects was brought up to Stub class.
BetacommandBot 14:54, 9 November 2007 (UTC)reply
Combination Therapies missing from Product list
Products like Azor and Trivasc (CS-8635) (still pending FDA approval in US) should be be included in the product line up.
Perhaps as a sub-bullet of Benicar, as they are derivatives of Benicar.
Also recently, DSI launched in Japan (4/16) Rezaltas (I think this is Trivasc from the description, not sure though). Can someone more knowledgeable confirm this?
http://www.daiichisankyo.com/news/2010_04_16_242e2.pdf
I made a change in the romanization of the company's name. In normal Japanese, the word for "Ltd" or "Inc" is pronounced "kabushiki-gaisha". However, after research I found that, in company names, the pronunciation "-kaisha" is also common. Regrettably, although I searched web pages in English as well as in Japanese, I was unable to find any info on this matter concerning this particular company.
Ceartaigh (
talk) 17:31, 29 March 2019 (UTC)reply
COI edit requests
This
edit request by an editor with a conflict of interest has now been answered.
Hi! I'm a COI editor representing Daiichi Sankyo (a client of my employer, Porter Novelli). I'd like to request some updates to this article:
Lead
In infobox, adding "Ken Keller (President and CEO, Daiichi Sankyo, Inc.)[1]" under "Key people". (Also, FYI, I previously updated the CEO listed in the infobox with ref, as I figured that would qualify as
WP:COIU.)
Also in infobox, updating financial figures and number of employees per latest annual report:
I did the USD/JPY conversion using the average annual exchange rate identified on page 90 of the report: 108.75.
Updating "It achieved JPY 2,305.4 billion in revenue in 2018." to "It achieved JPY 981.8 billion in revenue in 2019."
In third sentence, adding "American pharmaceutical company American Regent" to the list of subsidiaries, per the first suggested addition to "History" below.
History
Adding to first paragraph: In 1990, Sankyo acquired Luitpold-Werk Group, a pharmaceutical company based in
Munich.[3] In 2019, Luitpold renamed itself after its American Regent brand.[4] American Regent, now based in the United States, is a subsidiary of Daiichi Sankyo.[5][6]
Tweaking the opening of "Kickbacks" from Daiichi Sankyo is being "closely monitored"... to As of 2015, Daiichi Sankyo was being "closely monitored"...
In "Kickbacks", after As part of the company's Physician Organization and Discussion program, adding which ran from 2005 through 2011, (per the
source cited).
Adding after the U3 Pharma mention in "Acquisitions" (or as a new "Recent history" subsection?): Daiichi Sankyo closed U3 Pharma in 2015.[7]
Adding to end of "Acquisitions" (or as a new "Recent history" subsection?):
Daiichi Sankyo transferred 41 of its products in Japan to Alfresa Holdings Corporation for JPY 4.2 billion in 2018 in order to focus on oncology.[9]
In January 2020, the company's market value rose above JPY 5 trillion after the
U.S. Food and Drug Administration approval and release of
Enhertu,[10] an
antibody-drug conjugate for cancer treatment.[11] Daiichi Sankyo developed Enhertu in cooperation with
AstraZeneca,[10] which agreed in March 2019 to pay up to $6.9 billion to Daiichi Sankyo in exchange for a share of Enhertu's sales.[12][13]
Products
Updating the list accordingly:
Merging the two lists, since there are no sources provided for the division (nor is this how the company divides its products)
Updated through the products list. Note that Wikipedia is not for listing every product for every company. I've left the list as is and added a reference link to the company product list. ···
日本穣 ·
投稿 ·
Talk to Nihonjoe ·
Join WP Japan! 17:38, 15 June 2021 (UTC)reply
This
edit request by an editor with a
conflict of interest was declined. The reviewer has asked that the COI editor make changes before reviewing the request.
Hi! As noted above, I'm a COI editor representing Daiichi Sankyo (a client of my employer, Porter Novelli). I have some new requests for this article:
It achieved JPY 981.8 billion in revenue in 2019. The company owns the American biotechnology company
Plexxikon, American pharmaceutical company American Regent, German biotechnology company U3 Pharma, and recently sold
Ranbaxy Laboratories in India.
to
It achieved JPY 1,278 billion in revenue in 2022.[7] The company owns the American pharmaceutical company American Regent.
Plexxikon has been closed,[8][9] and it seems odd to me to include the former Ranbaxy ownership in the lead.
Update
Daiichi Sankyo Co., Ltd. is the producer of
Benicar (Olmesartan), an
angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen.
to
Daiichi Sankyo invented and is developing
Enhertu (trastuzumab deruxtecan),[10] a
HER2 directed
antibody-drug conjugate (ADC)[11] and the lead ADC in the company's oncology portfolio.[12]
Daiichi Sankyo's patent on Benicar expired several years ago;[13][14] Cosette Pharmaceuticals now holds US sales and distribution rights.[15] I think Enhertu makes sense as the callout here given Daiichi Sankyo's current focus on oncology and Enhertu as a major product.[16][10]
Acquisitions
Move
The shutdown of Plexxikon was announced in 2022[17] as Daiichi Sankyo pivots to focus on more antibody-drug conjugate therapies.[18]
from the end of the penultimate paragraph to the end of the third paragraph (the one about Plexxikon).
Delete
The transaction is set to close in December 2014, pending shareholder, court and regulatory approvals and other customary conditions.
This sentence is outdated and superseded by subsequent information.
In the sentence "On September 29, 2014, Daiichi Sankyo agreed to acquire
Ambit Biosciences for approximately $410 million, the deal enabled Daiichi to gain the Phase III cancer compound
quizartinib.[19]", delete "Phase III" – quizartinib is now approved for use in Japan[20] and in the United States.[21]
Update
Daiichi Sankyo developed Enhertu in cooperation with
AstraZeneca,[22]
to
Enhertu has been patented by Daiichi Sankyo[23] and is being co-developed and co-commercialized in cooperation with
AstraZeneca,[22]
I'm sorry, but this request needs a quick go-over before it's ready for review. There are several instances where two references are verifying the same information, which need to be consolidated into one reference. I'd also like to see Wikilinks for any |key people= who are not president, chairman or CEO (Wikilinks for Pipeline candidates as well) There is also the proposed text where we learn that Enhertu has been patented by Daiichi Sankyo and is being co-developed and co-commercialized in cooperation with AstraZeneca and then, later on in the text, we again discover that Daiichi Sankyo invented and is developing Enhertu (trastuzumab deruxtecan) Why are both of these passages of text being asked to be placed/re-placed into the article? Lastly, while on the subject of Enhertu, there is a HER2 directed antibody-drug conjugate (ADC) and the lead ADC in the company's oncology portfolio which is problematic, as the phrase "lead drug in their portfolio" sounds like something ripped from the company's website, which we can do without. Thank you in advance for these changes! Regards,
Spintendo 01:20, 20 October 2023 (UTC)reply
revised 2023 COI edit requests
Hi again – I've revised the edit requests below in response to the feedback above.
This
edit request by an editor with a conflict of interest has now been answered.
It achieved JPY 981.8 billion in revenue in 2019. The company owns the American biotechnology company
Plexxikon, American pharmaceutical company American Regent, German biotechnology company U3 Pharma, and recently sold
Ranbaxy Laboratories in India.
to
It achieved JPY 1,278 billion in revenue in 2022.[7] The company owns the American pharmaceutical company American Regent.
Plexxikon has been closed,[8] and it seems odd to me to include the former Ranbaxy ownership in the lead.
Update
Daiichi Sankyo Co., Ltd. is the producer of
Benicar (Olmesartan), an
angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen.
to
Daiichi Sankyo invented and is developing
Enhertu (trastuzumab deruxtecan),[9] a
HER2 directed
antibody-drug conjugate (ADC)[10] and the primary ADC in the company's oncology portfolio.[11]
Daiichi Sankyo's patent on Benicar expired several years ago;[12] Cosette Pharmaceuticals now holds US sales and distribution rights.[13] I think Enhertu makes sense as the callout here given Daiichi Sankyo's current focus on oncology and Enhertu as a major product.[14]
Acquisitions
Move
The shutdown of Plexxikon was announced in 2022[15] as Daiichi Sankyo pivots to focus on more antibody-drug conjugate therapies.[16]
from the end of the penultimate paragraph to the end of the third paragraph (the one about Plexxikon).
Delete
The transaction is set to close in December 2014, pending shareholder, court and regulatory approvals and other customary conditions.
This sentence is outdated and superseded by subsequent information.
In the sentence "On September 29, 2014, Daiichi Sankyo agreed to acquire
Ambit Biosciences for approximately $410 million, the deal enabled Daiichi to gain the Phase III cancer compound
quizartinib.[17]", delete "Phase III" – quizartinib is now approved for use in Japan[18] and in the United States.[19]
Update
Daiichi Sankyo developed Enhertu in cooperation with
AstraZeneca,[20]
to
Enhertu has been patented by Daiichi Sankyo[21] and is being co-developed and co-commercialized in cooperation with
AstraZeneca,[20]
Per
Spintendo's feedback above, noting I'm proposing Enhertu-related text for both the lead and Acquisitions section per
MOS:LEADNOTUNIQUE, specifically the guideline that the information in the lead should generally also appear in the body of the article.
Please let me know if there's any other feedback. Thank you for your time!
Mary Gaulke (
talk) 13:31, 4 December 2023 (UTC)reply
Approved The proposed Enhertu lead section was not included. The claim regarding Enhertu being "co-developed and co-commercialized" with AZ was not updated because the current wording is sufficient while the term "co-commercialized" may not be one that is easily recognized nor relevant to readers (that is, the fact that they're splitting the cost of advertising may not be relevant to all readers). Regards,
Spintendo 05:20, 25 December 2023 (UTC)reply
This article is within the scope of WikiProject Business, a collaborative effort to improve the coverage of
business articles on Wikipedia. If you would like to participate, please visit the project page, where you can join
the discussion and see a list of open tasks.BusinessWikipedia:WikiProject BusinessTemplate:WikiProject BusinessWikiProject Business articles
This article is within the scope of WikiProject Companies, a collaborative effort to improve the coverage of
companies on Wikipedia. If you would like to participate, please visit the project page, where you can join
the discussion and see a list of open tasks.CompaniesWikipedia:WikiProject CompaniesTemplate:WikiProject Companiescompany articles
This article is within the scope of WikiProject Japan, a collaborative effort to improve the coverage of Japan-related articles on Wikipedia. If you would like to
participate, please visit the
project page, where you can join the project, participate in
relevant discussions, and see
lists of open tasks. Current time in Japan: 14:02, June 17, 2024 (
JST,
Reiwa 6) (Refresh)JapanWikipedia:WikiProject JapanTemplate:WikiProject JapanJapan-related articles
This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of
Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join
the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
The
Wikimedia Foundation's
Terms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see
WP:PAID. For advice about reviewing paid contributions, see
WP:COIRESPONSE.
MaryGaulke (
talk·contribs) has been paid by Porter Novelli on behalf of Daiichi Sankyo.
Removed the erranous food/beverage analogy.
It doesn't belong in an encyclopedia entry for this company
Brettgo1 12:51, 22 October 2006 (UTC)reply
WikiProject class rating
This article was automatically assessed because at least one WikiProject had rated the article as stub, and the rating on other projects was brought up to Stub class.
BetacommandBot 14:54, 9 November 2007 (UTC)reply
Combination Therapies missing from Product list
Products like Azor and Trivasc (CS-8635) (still pending FDA approval in US) should be be included in the product line up.
Perhaps as a sub-bullet of Benicar, as they are derivatives of Benicar.
Also recently, DSI launched in Japan (4/16) Rezaltas (I think this is Trivasc from the description, not sure though). Can someone more knowledgeable confirm this?
http://www.daiichisankyo.com/news/2010_04_16_242e2.pdf
I made a change in the romanization of the company's name. In normal Japanese, the word for "Ltd" or "Inc" is pronounced "kabushiki-gaisha". However, after research I found that, in company names, the pronunciation "-kaisha" is also common. Regrettably, although I searched web pages in English as well as in Japanese, I was unable to find any info on this matter concerning this particular company.
Ceartaigh (
talk) 17:31, 29 March 2019 (UTC)reply
COI edit requests
This
edit request by an editor with a conflict of interest has now been answered.
Hi! I'm a COI editor representing Daiichi Sankyo (a client of my employer, Porter Novelli). I'd like to request some updates to this article:
Lead
In infobox, adding "Ken Keller (President and CEO, Daiichi Sankyo, Inc.)[1]" under "Key people". (Also, FYI, I previously updated the CEO listed in the infobox with ref, as I figured that would qualify as
WP:COIU.)
Also in infobox, updating financial figures and number of employees per latest annual report:
I did the USD/JPY conversion using the average annual exchange rate identified on page 90 of the report: 108.75.
Updating "It achieved JPY 2,305.4 billion in revenue in 2018." to "It achieved JPY 981.8 billion in revenue in 2019."
In third sentence, adding "American pharmaceutical company American Regent" to the list of subsidiaries, per the first suggested addition to "History" below.
History
Adding to first paragraph: In 1990, Sankyo acquired Luitpold-Werk Group, a pharmaceutical company based in
Munich.[3] In 2019, Luitpold renamed itself after its American Regent brand.[4] American Regent, now based in the United States, is a subsidiary of Daiichi Sankyo.[5][6]
Tweaking the opening of "Kickbacks" from Daiichi Sankyo is being "closely monitored"... to As of 2015, Daiichi Sankyo was being "closely monitored"...
In "Kickbacks", after As part of the company's Physician Organization and Discussion program, adding which ran from 2005 through 2011, (per the
source cited).
Adding after the U3 Pharma mention in "Acquisitions" (or as a new "Recent history" subsection?): Daiichi Sankyo closed U3 Pharma in 2015.[7]
Adding to end of "Acquisitions" (or as a new "Recent history" subsection?):
Daiichi Sankyo transferred 41 of its products in Japan to Alfresa Holdings Corporation for JPY 4.2 billion in 2018 in order to focus on oncology.[9]
In January 2020, the company's market value rose above JPY 5 trillion after the
U.S. Food and Drug Administration approval and release of
Enhertu,[10] an
antibody-drug conjugate for cancer treatment.[11] Daiichi Sankyo developed Enhertu in cooperation with
AstraZeneca,[10] which agreed in March 2019 to pay up to $6.9 billion to Daiichi Sankyo in exchange for a share of Enhertu's sales.[12][13]
Products
Updating the list accordingly:
Merging the two lists, since there are no sources provided for the division (nor is this how the company divides its products)
Updated through the products list. Note that Wikipedia is not for listing every product for every company. I've left the list as is and added a reference link to the company product list. ···
日本穣 ·
投稿 ·
Talk to Nihonjoe ·
Join WP Japan! 17:38, 15 June 2021 (UTC)reply
This
edit request by an editor with a
conflict of interest was declined. The reviewer has asked that the COI editor make changes before reviewing the request.
Hi! As noted above, I'm a COI editor representing Daiichi Sankyo (a client of my employer, Porter Novelli). I have some new requests for this article:
It achieved JPY 981.8 billion in revenue in 2019. The company owns the American biotechnology company
Plexxikon, American pharmaceutical company American Regent, German biotechnology company U3 Pharma, and recently sold
Ranbaxy Laboratories in India.
to
It achieved JPY 1,278 billion in revenue in 2022.[7] The company owns the American pharmaceutical company American Regent.
Plexxikon has been closed,[8][9] and it seems odd to me to include the former Ranbaxy ownership in the lead.
Update
Daiichi Sankyo Co., Ltd. is the producer of
Benicar (Olmesartan), an
angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen.
to
Daiichi Sankyo invented and is developing
Enhertu (trastuzumab deruxtecan),[10] a
HER2 directed
antibody-drug conjugate (ADC)[11] and the lead ADC in the company's oncology portfolio.[12]
Daiichi Sankyo's patent on Benicar expired several years ago;[13][14] Cosette Pharmaceuticals now holds US sales and distribution rights.[15] I think Enhertu makes sense as the callout here given Daiichi Sankyo's current focus on oncology and Enhertu as a major product.[16][10]
Acquisitions
Move
The shutdown of Plexxikon was announced in 2022[17] as Daiichi Sankyo pivots to focus on more antibody-drug conjugate therapies.[18]
from the end of the penultimate paragraph to the end of the third paragraph (the one about Plexxikon).
Delete
The transaction is set to close in December 2014, pending shareholder, court and regulatory approvals and other customary conditions.
This sentence is outdated and superseded by subsequent information.
In the sentence "On September 29, 2014, Daiichi Sankyo agreed to acquire
Ambit Biosciences for approximately $410 million, the deal enabled Daiichi to gain the Phase III cancer compound
quizartinib.[19]", delete "Phase III" – quizartinib is now approved for use in Japan[20] and in the United States.[21]
Update
Daiichi Sankyo developed Enhertu in cooperation with
AstraZeneca,[22]
to
Enhertu has been patented by Daiichi Sankyo[23] and is being co-developed and co-commercialized in cooperation with
AstraZeneca,[22]
I'm sorry, but this request needs a quick go-over before it's ready for review. There are several instances where two references are verifying the same information, which need to be consolidated into one reference. I'd also like to see Wikilinks for any |key people= who are not president, chairman or CEO (Wikilinks for Pipeline candidates as well) There is also the proposed text where we learn that Enhertu has been patented by Daiichi Sankyo and is being co-developed and co-commercialized in cooperation with AstraZeneca and then, later on in the text, we again discover that Daiichi Sankyo invented and is developing Enhertu (trastuzumab deruxtecan) Why are both of these passages of text being asked to be placed/re-placed into the article? Lastly, while on the subject of Enhertu, there is a HER2 directed antibody-drug conjugate (ADC) and the lead ADC in the company's oncology portfolio which is problematic, as the phrase "lead drug in their portfolio" sounds like something ripped from the company's website, which we can do without. Thank you in advance for these changes! Regards,
Spintendo 01:20, 20 October 2023 (UTC)reply
revised 2023 COI edit requests
Hi again – I've revised the edit requests below in response to the feedback above.
This
edit request by an editor with a conflict of interest has now been answered.
It achieved JPY 981.8 billion in revenue in 2019. The company owns the American biotechnology company
Plexxikon, American pharmaceutical company American Regent, German biotechnology company U3 Pharma, and recently sold
Ranbaxy Laboratories in India.
to
It achieved JPY 1,278 billion in revenue in 2022.[7] The company owns the American pharmaceutical company American Regent.
Plexxikon has been closed,[8] and it seems odd to me to include the former Ranbaxy ownership in the lead.
Update
Daiichi Sankyo Co., Ltd. is the producer of
Benicar (Olmesartan), an
angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen.
to
Daiichi Sankyo invented and is developing
Enhertu (trastuzumab deruxtecan),[9] a
HER2 directed
antibody-drug conjugate (ADC)[10] and the primary ADC in the company's oncology portfolio.[11]
Daiichi Sankyo's patent on Benicar expired several years ago;[12] Cosette Pharmaceuticals now holds US sales and distribution rights.[13] I think Enhertu makes sense as the callout here given Daiichi Sankyo's current focus on oncology and Enhertu as a major product.[14]
Acquisitions
Move
The shutdown of Plexxikon was announced in 2022[15] as Daiichi Sankyo pivots to focus on more antibody-drug conjugate therapies.[16]
from the end of the penultimate paragraph to the end of the third paragraph (the one about Plexxikon).
Delete
The transaction is set to close in December 2014, pending shareholder, court and regulatory approvals and other customary conditions.
This sentence is outdated and superseded by subsequent information.
In the sentence "On September 29, 2014, Daiichi Sankyo agreed to acquire
Ambit Biosciences for approximately $410 million, the deal enabled Daiichi to gain the Phase III cancer compound
quizartinib.[17]", delete "Phase III" – quizartinib is now approved for use in Japan[18] and in the United States.[19]
Update
Daiichi Sankyo developed Enhertu in cooperation with
AstraZeneca,[20]
to
Enhertu has been patented by Daiichi Sankyo[21] and is being co-developed and co-commercialized in cooperation with
AstraZeneca,[20]
Per
Spintendo's feedback above, noting I'm proposing Enhertu-related text for both the lead and Acquisitions section per
MOS:LEADNOTUNIQUE, specifically the guideline that the information in the lead should generally also appear in the body of the article.
Please let me know if there's any other feedback. Thank you for your time!
Mary Gaulke (
talk) 13:31, 4 December 2023 (UTC)reply
Approved The proposed Enhertu lead section was not included. The claim regarding Enhertu being "co-developed and co-commercialized" with AZ was not updated because the current wording is sufficient while the term "co-commercialized" may not be one that is easily recognized nor relevant to readers (that is, the fact that they're splitting the cost of advertising may not be relevant to all readers). Regards,
Spintendo 05:20, 25 December 2023 (UTC)reply